Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01979874 · ClinicalTrials.gov registry record · Phase 2

The Effects of Omega-3 Fatty Acids on Peripheral Arterial Disease II

A Phase 2 study, sponsored by University of California, San Francisco.

Completed
Registry status
Phase 2
Development phase
26
Enrollment target

NCT01979874 is a Phase 2 study that has completed, run by University of California, San Francisco. The registered enrollment target is 26 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01979874, a Phase 2 study, has completed, sponsored by University of California, San Francisco.

COMPLETED
Registry status
Phase 2
Development phase
26 participants
Enrollment target

Study Summary

Investigators hypothesize that high-dose n-3 polyunsaturated fatty acids (PUFA) oral supplementation will improve systemic inflammation, vascular function, and symptomatic status of patients with PAD. Investigators will explore novel mechanistic pathways by which n-3 PUFA affect PAD, evaluating the role of specialized lipid mediators involved in the resolution of inflammation.

Interventions

  • DIETARY_SUPPLEMENT Pro-Omega
  • OTHER ProOmega Placebo

Trial Details

FieldValue
Enrollment Target 26 participants
Start Date 2014-02
Est. Completion 2017-09
Phase Phase 2

What the Registry Record Tells You About NCT01979874

The ClinicalTrials.gov registry entry for NCT01979874 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Pro-Omega is the first listed.

NCT01979874 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01979874 about?

NCT01979874 is a clinical study titled "The Effects of Omega-3 Fatty Acids on Peripheral Arterial Disease II". Investigators hypothesize that high-dose n-3 polyunsaturated fatty acids (PUFA) oral supplementation will improve systemic inflammation, vascular function, and symptomatic status of patients with PAD. Investigators will explore novel mechanistic pathways by which n-3 PUFA affect PAD, evaluating the ...

What is the current status of trial NCT01979874?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2014-02. Estimated completion is 2017-09.

What interventions are being tested in trial NCT01979874?

The interventions under investigation include: Pro-Omega (DIETARY_SUPPLEMENT), ProOmega Placebo (OTHER).

Who is sponsoring clinical trial NCT01979874?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.